Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS Report No. 11

Neil M Bressler, Susan B Bressler, Nathan G. Congdon, Frederick L. Ferris, David S Friedman, Ronald Klein, Anne S. Lindblad, Roy C. Milton, Johanna M. Seddon

Research output: Contribution to journalArticle

Abstract

Objective: To estimate the potential public health impact of the findings of the Age-Related Eye Disease Study (AREDS) on reducing the number of persons developing advanced age-related macular degeneration (AMD) during the next 5 years in the United States. Methods: The AREDS clinical trial provides estimates of AMD progression rates and of reduction in risk of developing advanced AMD when a high-dose nutritional supplement of antioxidants and zinc is used. These results are applied to estimates of the US population at risk, to estimate the number of people who would potentially avoid advanced AMD during 5 years if those at risk were to take a supplement such as that used in AREDS. Results: An estimated 8 million persons at least 55 years old in the United States have monocular or binocular intermediate AMD or monocular advanced AMD. They are considered to be at high risk for advanced AMD and are those for whom the AREDS formulation should be considered. Of these people, 1.3 million would develop advanced AMD if no treatment were given to reduce their risk. If all of these people at risk received supplements such as those used in AREDS, more than 300000 (95% confidence interval, 158000-487000) of them would avoid advanced AMD and any associated vision loss during the next 5 years. Conclusion: If people at high risk for advanced AMD received supplements such as those suggested by AREDS results, the potential impact on public health in the United States would be considerable during the next 5 years.

Original languageEnglish (US)
Pages (from-to)1621-1624
Number of pages4
JournalArchives of Ophthalmology
Volume121
Issue number11
DOIs
StatePublished - Nov 2003
Externally publishedYes

Fingerprint

Eye Diseases
Macular Degeneration
Public Health
Risk Reduction Behavior
Zinc
Antioxidants
Clinical Trials
Confidence Intervals

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Potential Public Health Impact of Age-Related Eye Disease Study Results : AREDS Report No. 11. / Bressler, Neil M; Bressler, Susan B; Congdon, Nathan G.; Ferris, Frederick L.; Friedman, David S; Klein, Ronald; Lindblad, Anne S.; Milton, Roy C.; Seddon, Johanna M.

In: Archives of Ophthalmology, Vol. 121, No. 11, 11.2003, p. 1621-1624.

Research output: Contribution to journalArticle

Bressler, Neil M ; Bressler, Susan B ; Congdon, Nathan G. ; Ferris, Frederick L. ; Friedman, David S ; Klein, Ronald ; Lindblad, Anne S. ; Milton, Roy C. ; Seddon, Johanna M. / Potential Public Health Impact of Age-Related Eye Disease Study Results : AREDS Report No. 11. In: Archives of Ophthalmology. 2003 ; Vol. 121, No. 11. pp. 1621-1624.
@article{b058d0d21bb34244ae5e161f31348d8f,
title = "Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS Report No. 11",
abstract = "Objective: To estimate the potential public health impact of the findings of the Age-Related Eye Disease Study (AREDS) on reducing the number of persons developing advanced age-related macular degeneration (AMD) during the next 5 years in the United States. Methods: The AREDS clinical trial provides estimates of AMD progression rates and of reduction in risk of developing advanced AMD when a high-dose nutritional supplement of antioxidants and zinc is used. These results are applied to estimates of the US population at risk, to estimate the number of people who would potentially avoid advanced AMD during 5 years if those at risk were to take a supplement such as that used in AREDS. Results: An estimated 8 million persons at least 55 years old in the United States have monocular or binocular intermediate AMD or monocular advanced AMD. They are considered to be at high risk for advanced AMD and are those for whom the AREDS formulation should be considered. Of these people, 1.3 million would develop advanced AMD if no treatment were given to reduce their risk. If all of these people at risk received supplements such as those used in AREDS, more than 300000 (95{\%} confidence interval, 158000-487000) of them would avoid advanced AMD and any associated vision loss during the next 5 years. Conclusion: If people at high risk for advanced AMD received supplements such as those suggested by AREDS results, the potential impact on public health in the United States would be considerable during the next 5 years.",
author = "Bressler, {Neil M} and Bressler, {Susan B} and Congdon, {Nathan G.} and Ferris, {Frederick L.} and Friedman, {David S} and Ronald Klein and Lindblad, {Anne S.} and Milton, {Roy C.} and Seddon, {Johanna M.}",
year = "2003",
month = "11",
doi = "10.1001/archopht.121.11.1621",
language = "English (US)",
volume = "121",
pages = "1621--1624",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Potential Public Health Impact of Age-Related Eye Disease Study Results

T2 - AREDS Report No. 11

AU - Bressler, Neil M

AU - Bressler, Susan B

AU - Congdon, Nathan G.

AU - Ferris, Frederick L.

AU - Friedman, David S

AU - Klein, Ronald

AU - Lindblad, Anne S.

AU - Milton, Roy C.

AU - Seddon, Johanna M.

PY - 2003/11

Y1 - 2003/11

N2 - Objective: To estimate the potential public health impact of the findings of the Age-Related Eye Disease Study (AREDS) on reducing the number of persons developing advanced age-related macular degeneration (AMD) during the next 5 years in the United States. Methods: The AREDS clinical trial provides estimates of AMD progression rates and of reduction in risk of developing advanced AMD when a high-dose nutritional supplement of antioxidants and zinc is used. These results are applied to estimates of the US population at risk, to estimate the number of people who would potentially avoid advanced AMD during 5 years if those at risk were to take a supplement such as that used in AREDS. Results: An estimated 8 million persons at least 55 years old in the United States have monocular or binocular intermediate AMD or monocular advanced AMD. They are considered to be at high risk for advanced AMD and are those for whom the AREDS formulation should be considered. Of these people, 1.3 million would develop advanced AMD if no treatment were given to reduce their risk. If all of these people at risk received supplements such as those used in AREDS, more than 300000 (95% confidence interval, 158000-487000) of them would avoid advanced AMD and any associated vision loss during the next 5 years. Conclusion: If people at high risk for advanced AMD received supplements such as those suggested by AREDS results, the potential impact on public health in the United States would be considerable during the next 5 years.

AB - Objective: To estimate the potential public health impact of the findings of the Age-Related Eye Disease Study (AREDS) on reducing the number of persons developing advanced age-related macular degeneration (AMD) during the next 5 years in the United States. Methods: The AREDS clinical trial provides estimates of AMD progression rates and of reduction in risk of developing advanced AMD when a high-dose nutritional supplement of antioxidants and zinc is used. These results are applied to estimates of the US population at risk, to estimate the number of people who would potentially avoid advanced AMD during 5 years if those at risk were to take a supplement such as that used in AREDS. Results: An estimated 8 million persons at least 55 years old in the United States have monocular or binocular intermediate AMD or monocular advanced AMD. They are considered to be at high risk for advanced AMD and are those for whom the AREDS formulation should be considered. Of these people, 1.3 million would develop advanced AMD if no treatment were given to reduce their risk. If all of these people at risk received supplements such as those used in AREDS, more than 300000 (95% confidence interval, 158000-487000) of them would avoid advanced AMD and any associated vision loss during the next 5 years. Conclusion: If people at high risk for advanced AMD received supplements such as those suggested by AREDS results, the potential impact on public health in the United States would be considerable during the next 5 years.

UR - http://www.scopus.com/inward/record.url?scp=0242526930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242526930&partnerID=8YFLogxK

U2 - 10.1001/archopht.121.11.1621

DO - 10.1001/archopht.121.11.1621

M3 - Article

C2 - 14609922

AN - SCOPUS:0242526930

VL - 121

SP - 1621

EP - 1624

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 11

ER -